U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection

Dear Colleagues,

This Special Issue highlights the collaborative innovation emerging from our integrated myeloma research programs, dedicated to transforming outcomes through next-generation immunotherapy, cellular therapy, and precision-based translational science. Our projects span the full spectrum of immune-based strategies—including CAR-T cells, T-cell engagers (TCEs), bispecific and trispecific platforms, and novel targets such as BCMA, GPRC5D, and emerging noncanonical antigens. In partnership with national and international collaborators across academic centers, cooperative groups, and the U.S. Myeloma Innovations Research Collaborative (USMIRC), our work aims to define mechanisms of resistance, optimize sequencing, and expand access to cutting-edge therapies for patients with multiple myeloma and other plasma cell disorders. Together, these initiatives create a multidisciplinary ecosystem accelerating discovery, clinical translation, and real-world impact.

Dr. Al-Ola A. Abdallah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Publisher’s Notice:

As stated above, the central purpose of this Special Issue is to present research from U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection. Given this purpose, the Guest Editors’ contribution to this Special Issue may be greater than standard Special Issues published by MDPI. Further details on MDPI's Special Issue guidelines can be found here: https://www.mdpi.com/special_issues_guidelines. The Editorial Office and Editor-in-Chief of Current Oncology has approved this and MDPI’s standard manuscript editorial processing procedure (https://www.mdpi.com/editorial_process) will be applied to all submissions. As per our standard procedure, Guest Editors are excluded from participating in the editorial process for their submission and/or for submissions from persons with whom a potential conflict of interest may exist. More details on MDPI’s Conflict of Interest policy for reviewers and editors can be found here: https://www.mdpi.com/ethics#_bookmark22.